Search

Pharmagest Interactive

Slēgts

0

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

Galvenie mērījumi

By Trading Economics

Ienākumi

-1.8M

17M

Pārdošana

7.2M

116M

P/E

Sektora vidējais

16.213

Dividenžu ienesīgums

3.08

Peļņas marža

14.879

Darbinieki

1,400

EBITDA

178M

116M

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.08%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-24M

583M

Iepriekšējā atvēršanas cena

0

Iepriekšējā slēgšanas cena

0

Pharmagest Interactive Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 28. okt. 23:50 UTC

Karstas akcijas

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

2025. g. 28. okt. 23:25 UTC

Peļņas

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

2025. g. 28. okt. 23:18 UTC

Peļņas

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

2025. g. 28. okt. 22:20 UTC

Peļņas

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

2025. g. 28. okt. 22:13 UTC

Peļņas

Wal-Mart de Mexico Net Profit Falls in 3Q

2025. g. 28. okt. 21:38 UTC

Peļņas

Correction to Visa Sales Jump Article

2025. g. 28. okt. 21:17 UTC

Peļņas

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

2025. g. 28. okt. 21:07 UTC

Peļņas

Visa Sales Jump as Consumers Keep Spending -- Update

2025. g. 28. okt. 21:02 UTC

Peļņas

Mondelez Tempers Outlook as Costs Rise

2025. g. 28. okt. 23:51 UTC

Tirgus saruna

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

2025. g. 28. okt. 23:42 UTC

Tirgus saruna

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

2025. g. 28. okt. 23:02 UTC

Peļņas

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

2025. g. 28. okt. 23:01 UTC

Peļņas

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

2025. g. 28. okt. 22:46 UTC

Peļņas

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

2025. g. 28. okt. 22:45 UTC

Peļņas

SK Hynix 3Q Net KRW12.6T >000660.SE

2025. g. 28. okt. 22:44 UTC

Peļņas

SK Hynix 3Q Rev KRW24.44T >000660.SE

2025. g. 28. okt. 22:43 UTC

Peļņas

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

2025. g. 28. okt. 22:42 UTC

Peļņas

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

2025. g. 28. okt. 22:40 UTC

Peļņas

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

2025. g. 28. okt. 22:40 UTC

Peļņas

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

2025. g. 28. okt. 22:22 UTC

Peļņas

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

2025. g. 28. okt. 22:22 UTC

Peļņas

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

2025. g. 28. okt. 22:22 UTC

Peļņas

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

2025. g. 28. okt. 22:20 UTC

Peļņas

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

2025. g. 28. okt. 22:02 UTC

Peļņas

Review & Preview: Earnings Extravaganza -- Barrons.com

2025. g. 28. okt. 21:42 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 28. okt. 21:42 UTC

Tirgus saruna
Peļņas

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

2025. g. 28. okt. 21:20 UTC

Peļņas

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

2025. g. 28. okt. 21:19 UTC

Peļņas

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

2025. g. 28. okt. 21:18 UTC

Peļņas

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Pharmagest Interactive Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

0

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Pharmagest Interactive

Equasens Société anonyme provides healthcare IT solutions in Europe. The company develops electronic equipment, digital and robotic health, and equipment lease financing solutions. It also offers id., a pharmacy management software suite; id. PATIENT for the exchange of healthcare data; id. VENTE, which facilitates and secures prescription sales; id. COMMANDE, which manages orders and inventory; dispensing robots; Ségur id. services; FARMACLICK, a communication protocol; DIFARM, a modular solution for wholesalers-distributors; and PHARE, a retail management tool. In addition, the company offers patient medication adherence, patient loyalty, point-of-sale commercial performance, piloting pharmacy operations, pharmacy team training, securing pharmacy operations and health data, and digital communication solutions; and in-home nursing services and hospital-at-home, hospitals, and telemedicine solutions. Further, it provides id. DESK, an informative and interactive dashboard; id. UP!, a smartphone app; id. EASYQ, a queuing management solution; Miaterapia, a patient app; and MediStory for tracking patient records; ExpressVitale module; and MEDILINK, a health data hosting provider. Additionally, the company offers KAP&LINK2, a terminal with smart card and NFC reader; eS-KAP-Ad, a mobile device with a pre-loaded software; KAP-INSIDE, a mobile terminal; TI-KAP, which allows access to contact and contactless cards; AUTHENTIFICATEUR, a patented patient authentication system; KAP'TEUR by KAPELSE, a patented universal sensor; and NOVIAcare, which analyzes the behavior and activity of the elderly. It serves nursing homes, hospitals, in-house nursing care and hospital-at-home programs, regional health professional communities, multidisciplinary group practices, and individual healthcare professionals. The company was incorporated in 1996 and is headquartered in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
help-icon Live chat